A paradigm shift is occurring for the management of nonproliferative diabetic retinopathy, with new evidence demonstrating that patients with moderately-severe to severe nonproliferative diabetic retinopathy can benefit from anti-VEGF treatment. Join Dr. Mark Dunbar and Dr. Jay Haynie as they discuss the evidence for this evolution and what optometrists need to know to protect the vision of their patients with diabetic eye disease.

Vision loss caused by diabetic retinopathy can have a significant impact on a patient's quality of life. This activity emphasizes more assertive action in clinical practice for patient with diabetes. The acronym ASSERT-D is a reminder to Assess and Screen for Eye health and Refer or Treat patients with Diabetes.

As the primary care providers of our patients’ eye health, it’s important for optometrists to be assertive with screening and following patients with diabetes so that they’re appropriately referred when retinopathy and/or macular edema develops. Join Dr. Mark Dunbar as he interviews Dr. Diana Shechtman to uncover best practices for identifying suspected diabetic retinopathy and/or macular edema in at-risk patients.

Vision loss caused by diabetic retinopathy can have a significant impact on a patient's quality of life. This activity emphasizes more assertive action in clinical practice for patient with diabetes. The acronym ASSERT-D is a reminder to Assess and Screen for Eye health and Refer or Treat patients with Diabetes.

Unfortunately, there are many factors that can contribute to a patient’s risk for vision-threatening complications and vision loss due to diabetes. Explore those factors with Dr. Anne Peters, Dr. Thomas Gardner, and Dr. Diana Shechtman, who also discuss how endocrinologists and primary care providers can work together with eye care professionals to actively optimize vision outcomes for patients at risk for diabetic retinopathy and diabetic macular edema.

Vision loss caused by diabetic retinopathy can have a significant impact on a patient's quality of life. This activity emphasizes more assertive action in clinical practice for patient with diabetes. The acronym ASSERT-D is a reminder to Assess and Screen for Eye health and Refer or Treat patients with Diabetes.

With clinical trials showing improvements over the current standard of care for HER2+ early breast cancer, incorporating new data and medications into this treatment paradigm is becoming a top priority. Listen in as Dr. Charles Geyer reviews the emerging approaches to adjuvant therapy in patients with HER2+ early breast cancer.

The newer option that’s available to treat the flu is not a neuraminidase inhibitor, but an endonuclease inhibitor, and both work differently in their approach to reducing the viral load and the viral shedding of the flu virus. This activity will discuss how we can integrate these options into personalized treatment plans and the impact of influenza on at-risk and high-risk individuals.

Since the launch of the activity, the US FDA has approved a new indication for baloxavir marboxil to include the treatment of acute, uncomplicated influenza in people 12 years of age and older who have been symptomatic for no more than 48 hours, who are otherwise healthy, or who are at high risk of developing flu-related complications.

The newer option that’s available to treat the flu is not a neuraminidase inhibitor, but an endonuclease inhibitor, and both work differently in their approach to reducing the viral load and the viral shedding of the flu virus. This activity will discuss how we can integrate these options into personalized treatment plans and the impact of influenza on at-risk and high-risk individuals.

Since the launch of the activity, the US FDA has approved a new indication for baloxavir marboxil to include the treatment of acute, uncomplicated influenza in people 12 years of age and older who have been symptomatic for no more than 48 hours, who are otherwise healthy, or who are at high risk of developing flu-related complications.

Advancements in the treatment of ulcerative colitis (UC) have given us the ability to control patient symptoms, achieve inflammation control, prolong remission, and prevent disease progression. Join Dr. David Rubin as he discusses how biologic therapies and small molecule DMARDs play a role in the UC treatment paradigm.

What’s the difference between a neuraminidase inhibitor and an endonuclease inhibitor? That’s what this activity will explore, in addition to how this new endonuclease inhibitor works, if it’s for everyone, and which biologic pathways and related MOAs for antiviral agents are effective against influenza A and B.

Since the launch of the activity, the US FDA has approved a new indication for baloxavir marboxil to include the treatment of acute, uncomplicated influenza in people 12 years of age and older who have been symptomatic for no more than 48 hours, who are otherwise healthy, or who are at high risk of developing flu-related complications.

Recently released data and publications have started to change the discussion on family planning for patients with MS. And to help put those recommendations into action, this activity will review a case commonly seen by neurologists as well as women’s health professionals, while offering new perspectives and opportunities for this unique patient group.

A pesar del progreso monumental realizado en el tratamiento molecular dirigido en el cáncer pulmonar de células no pequeñas (CPCNP), la mayoría de los pacientes en América Latina todavía no reciben pruebas moleculares recomendadas para guiar las decisiones de tratamiento personalizadas. Por ende, los resultados para CPCNP siguen siendo subóptimos.

Esta actividad está diseñada para médicos oncólogos, cirujanos, patólogos y otras profesiones clínicas en América Latina que requieren más información sobre el papel de los nuevos biomarcadores como PD-L1, así como la importancia de la toma de la muestra de biopsa, el manejo del tejido, y los requerimientos para cada prueba molecular en CPCNP.

La integración más amplia de las pruebas moleculares es crucial y requerirá que los médicos adopten un enfoque interprofesional para el manejo optimo del paciente.